Related by context. All words. (Click for frequent words.) 72 median PFS 70 Median progression 69 progression TTP 68 evaluable 66 free survival PFS 66 FOLFOX4 66 Median PFS 66 CCyR 66 biochemical recurrence 66 Free Survival PFS 65 achieved ACR# 65 locoregional recurrence 65 % CI #.#-#.# [003] 65 placebo dexamethasone 64 Baseline characteristics 64 FOLFOX4 alone 64 stage IIIb IV 64 comparator arm 64 underwent resection 64 mcg albinterferon alfa 2b 64 PSADT 63 underwent surgical resection 63 mg QD 63 evaluable subjects 63 heavily pretreated 63 plus dexamethasone 63 chlorambucil 63 mg kg dose 63 FOLFOX 63 stage IIIB IV 63 pCR 63 CR nPR 63 Folfox 63 recurrent VTE 63 complete cytogenetic 63 biochemical relapse 63 neurologic progression 62 FOLFIRI alone 62 preoperative chemotherapy 62 definite stent thrombosis 62 sustained virologic response 62 ipsilateral stroke 62 patients evaluable 62 LVEF 62 mg/m2 62 mRCC 62 locoregional 62 KRAS wild 62 glioblastomas 62 mg m² 62 KRAS mutations occur 62 #mg BID [001] 62 lopinavir r arm 62 tumor progression TTP 61 leukemia AML 61 advanced adenomas 61 interferon alfa 61 distant metastasis 61 metastatic renal cell carcinoma 61 fluorouracil 61 Flu Cy 61 Kaplan Meier analysis 61 peginterferon alfa 2a 61 dacarbazine 61 recurrent GBM 61 cGy 61 pegylated interferon alfa 2b 61 mitoxantrone 61 mg/m2 IV 61 % CI #.#-#.# [007] 61 carboplatin paclitaxel 61 complete cytogenetic response 61 plus gemcitabine 61 tumor shrinkage 61 underwent liver transplantation 61 preintervention 61 daunorubicin 61 mcg kg 61 virologic failure 61 5-FU/LV 61 aged ≥ 61 FOLFIRI 61 neoadjuvant therapy 61 squamous histology 61 HBeAg positive patients 61 prior chemotherapy regimens 61 Scale EDSS 61 CMV disease 60 distant metastases 60 binary restenosis 60 advanced adenoma 60 undetectable HBV DNA 60 #mg QD [001] 60 nondiabetic patients 60 IV NSCLC 60 #mg/m# [002] 60 pegylated liposomal doxorubicin 60 mg TID 60 endoscopic remission 60 mg/m2/day 60 relapsed MM 60 Peg IFN 60 iniparib BSI 60 undetectable HCV RNA 60 tamoxifen therapy 60 MACCE 60 QTcF 60 bortezomib refractory 60 cancer mCRC 60 receiving highly emetogenic 60 estramustine 60 dosing cohorts 60 docetaxel chemotherapy 60 anthracycline taxane 60 achieved PASI 60 MADRS score 60 febrile neutropenia 60 tumor recurrence 60 % Confidence Interval 60 ribavirin RBV 60 hours postdose 60 undergone radical prostatectomy 60 seroprotection 60 g dL 60 severe neutropenia 60 octreotide LAR 60 nonmetastatic 60 resected pancreatic cancer 60 CRp 60 conventional IMRT 60 ng mL 60 unresectable stage 60 Psoriasis Area 60 REYATAZ r arm 60 pegylated interferon alfa 2a 60 #.#ng/ml 60 prior nephrectomy 60 neoadjuvant chemotherapy 60 CYPHER Stent 60 lymph node involvement 60 interquartile range 59 evaluable patients 59 ertapenem 59 #mg QD [002] 59 P = .# 59 HbA1c levels 59 metastatic RCC 59 standard chemotherapy regimen 59 eribulin 59 flutamide 59 NATRECOR R 59 μg dose 59 RECIST criteria 59 Doxil ® 59 postoperative chemotherapy 59 pT3 59 operable breast cancer 59 clodronate 59 plasma uric acid 59 adjuvant chemotherapy 59 chemoradiotherapy 59 MELD scores 59 temsirolimus 59 Fludara 59 placebo PBO 59 partial remissions 59 XELOX 59 Rectal cancer 59 cabazitaxel 59 nondiabetic 59 gemcitabine chemotherapy 59 heavily pretreated patients 59 mg/m2 dose 59 pegylated interferon alpha 59 ALND 59 low dose Iluvien 59 8mg/kg 59 cytarabine daunorubicin 59 RGT arm 59 chemoradiation 59 achieved CCyR 59 metastatic GIST 59 metastatic renal cell 59 HBeAg negative 59 cytogenetic response 59 cytoreduction 59 liver metastases 59 radical nephrectomy 59 lamivudine monotherapy 59 PSA nadir 59 FluCAM arm 59 virologic response 59 decitabine 59 EBRT 59 TORISEL 59 cytogenetic responses 59 receiving VICTRELIS 59 lobular cancer 59 median survivals 59 undetectable virus HCV 59 response CCyR 59 dose dexamethasone 59 pancreatic adenocarcinoma 59 ng dL 59 naïve HCV 59 mg BID 59 Q2W 58 postintervention 58 amoxicillin clavulanate 58 mcg dose 58 CYPHER R Stent 58 pomalidomide 58 nonsmall cell lung cancer 58 sunitinib 58 stage IIIB 58 recurrent glioblastoma multiforme 58 antiretroviral naive 58 detectable HCV RNA 58 etanercept 58 TAXUS Express Stent 58 q#h 58 mg m 58 HER2 positive metastatic breast 58 imatinib therapy 58 aminotransferase elevations greater 58 low dose cytarabine 58 rapid virologic response 58 CIMZIA TM 58 receiving prophylactic anticoagulation 58 HCV genotype 58 topotecan 58 remission induction 58 EGFR TKI 58 idarubicin 58 metastatic lung cancer 58 specific antigen PSA 58 Kaplan Meier estimate 58 mg ustekinumab 58 coinfected 58 KRAS mutant tumors 58 #mg ATC 58 papillary renal cell carcinoma 58 undetectable viral load 58 PREZISTA ritonavir 58 lumbar spine BMD 58 Zometa hazard 58 Engerix B 58 mcg Albuferon 58 LEXIVA r 58 CR CRu 58 infusional 5-FU/LV 58 tumor histology 58 Jevtana 58 underwent radical prostatectomy 58 receiving ISENTRESS 58 clinically localized prostate 58 Kaplan Meier 58 adjuvant therapy 58 neoadjuvant 58 RECIST Response Evaluation Criteria 58 PASI scores 58 pancreatic NET 58 histologically confirmed 58 gastrointestinal stromal tumor GIST 58 radiochemotherapy 58 vandetanib 58 #mg dose [002] 58 chemoradiation therapy 58 tipranavir r 58 mycophenolate mofetil 58 methotrexate monotherapy 58 mitoxantrone plus 58 pamidronate 58 NNRTI resistance 58 androgen deprivation 58 docetaxel 58 alfa 2a 58 mCi kg 58 oral clodronate 58 infliximab monotherapy 58 leukemia ALL 58 plus prednisone 58 adjuvant tamoxifen 58 PREZISTA r 58 HIV HCV coinfected 58 oxycodone CR 58 hematologic toxicity 58 Response Evaluation Criteria 58 CC genotype 58 autoantibody positive 58 remission CR 58 log# copies mL 58 IV melanoma 58 EDSS score 58 IU ml 58 Solid Tumors criteria 58 EGFR mutation positive 58 HBeAg negative patients 58 μmol L 58 Operative mortality 58 alemtuzumab treated 57 confirmed CCyR 57 plus methotrexate 57 pg mL 57 localized renal 57 ACR# response 57 gefitinib 57 Hazard Ratio 57 dose cohort 57 recurrent wheezing 57 graft occlusion 57 Partial Responses 57 acute leukemias 57 colorectal metastases 57 advanced NSCLC 57 peg IFN 57 workhorse lesions 57 microbiological eradication 57 mg d 57 Index CDAI score 57 refractory CTCL 57 HCV infected 57 events SAEs 57 SUVmax 57 highly emetogenic 57 posttransplant 57 metastatic malignant melanoma 57 antithymocyte globulin 57 CHOP chemotherapy 57 baseline A1C 57 glufosfamide 57 sirolimus eluting stent 57 mg administered orally 57 peginterferon 57 cisplatin chemotherapy 57 mcg QD 57 #mg BID [002] 57 recurrent NSCLC 57 p = NS 57 FluCAM 57 CYPHER ® Stent 57 IR Cysteamine 57 p = #.# [004] 57 sorafenib Nexavar ® 57 azacitidine 57 baseline HbA1c 57 pmol liter 57 atypical hyperplasia 57 dose cohorts 57 abacavir lamivudine 57 metastatic disease 57 certolizumab 57 #mg/m# [001] 57 MCyR 57 Taxus Stent 57 Torisel 57 disease progression 57 lymphocytosis 57 baseline Hb 57 VIDAZA 57 HCV RESPOND 2 57 standard chemotherapy regimens 57 dalteparin 57 mg RDEA# 57 metastatic hormone refractory 57 5-fluorouracil/leucovorin 57 interferon alfa 2a 57 lopinavir r 57 timepoints 57 untreated mice 57 #mg BID [003] 57 invasive carcinomas 57 completely resected 57 hepatorenal syndrome 57 FLT3 ITD 57 BARACLUDE ® 57 castration resistant prostate cancer 57 locoregional disease 57 oblimersen 57 nonfatal MI 57 TTF Therapy 57 mg simvastatin 57 ErbB2 positive 57 achieved sustained virological 57 brain metastases 57 metastatic castration resistant 57 pancreatic neuroendocrine tumors 57 VaD 57 noncarriers 57 adult chronic ITP 57 dacarbazine chemotherapy 57 seroconverted 57 Severity Index PASI 57 Stent thrombosis 57 #mg/kg [002] 57 NMIBC 57 prednisone prednisolone 57 systemic ALCL 57 ng ml 57 severe psoriasis 57 paclitaxel cisplatin 57 adjunctive placebo 57 gemcitabine 57 HSCT 57 sUA 57 androgen suppression 57 undetectable viral 57 TAXUS Stent 57 curative resection 57 underwent CABG 57 colorectal liver metastases 57 HER2 negative 57 platinum refractory 57 basal cell carcinoma BCC 57 Tumors shrank 57 VELCADE melphalan 57 metastatic kidney 56 euthyroid 56 4mg/kg 56 mg Lucentis 56 carboplatin 56 gemcitabine carboplatin 56 hepatitis C genotype 56 FOLFOX6 56 pT2 56 Viread Emtriva Sustiva 56 unfractionated heparin 56 preoperative PSA 56 renal cell carcinomas 56 unresectable 56 Partial Response 56 stent thromboses 56 achieved sustained virologic 56 XIENCE V vs. 56 EpCAM expression 56 non metastatic osteosarcoma 56 pegylated interferon peg IFN 56 VcMP 56 CLL SLL 56 symptom onset 56 TAXUS p value 56 adriamycin 56 lung metastases 56 de novo AML 56 Bezielle 56 gastrointestinal stromal tumors 56 oral Hycamtin 56 dapagliflozin plus 56 neoadjuvant treatment 56 PEG IFN 56 trastuzumab 56 HCV SPRINT 56 ACR# responses 56 adalimumab 56 antiretroviral naïve 56 QT intervals 56 doxorubicin cyclophosphamide 56 diagnosed GBM 56 acute coronary syndromes ACS 56 taxane chemotherapy 56 sd = 56 imatinib 56 primary hypercholesterolemia 56 oral diclofenac 56 refractory acute myeloid 56 sirolimus stent 56 GnRH agonist 56 stage IIIb 56 statistically significant p = 56 ACTEMRA TM 56 paroxysmal AF 56 elevated ALT 56 A1c levels 56 #mg/day [001] 56 seminoma 56 methotrexate therapy 56 mCRC patients 56 ximelagatran 56 systemic embolism 56 DAS# [002] 56 histologies 56 sustained virological response 56 splenectomized patients 56 CTEPH 56 receiving golimumab 56 CTAP# Capsules 56 DMARDs 56 dacarbazine DTIC 56 confidence interval CI 56 angiographic outcomes 56 histologic subtype 56 telaprevir dosed 56 hormone receptor negative 56 HBsAg 56 oral allopurinol 56 mL/min/#.# m 2 56 TAXUS VI 56 mm Stent 56 HBeAg positive 56 azathioprine 56 hA# 56 plus MTX 56 thymoma 56 plus OBT 56 differentiated thyroid 56 virological failure 56 mCRPC 56 infliximab 56 paclitaxel eluting stents 56 carboplatin chemotherapy 56 pmol L 56 IFN alfa 56 μg L 56 DAS# CRP 56 adefovir 56 HbA 1c levels 56 systolic dysfunction 56 piperacillin tazobactam 56 advanced neoplasia 56 ER CHOP 56 non squamous histology 56 Subgroup analysis 56 lymphoid malignancies 56 IFL chemotherapy regimen 56 hsCRP levels 56 serum phosphate 56 unresectable tumors 56 K ras mutations 56 RECORD1 56 prospectively defined 56 EGFR mutations 56 XIENCE V PROMUS Stent 56 postmenopausal osteoporotic women 56 BEACOPP 56 poor metabolizers 56 ritonavir boosted atazanavir 56 interferon alpha 56 adalimumab Humira 56 Amrubicin 56 doxorubicin docetaxel 56 HBeAg seroconversion 56 CrCl 56 cisplatin vinorelbine 56 DAPT 56 PREZISTA rtv 56 discontinuations due 56 cisplatin gemcitabine 56 lymphadenectomy 56 refractory NSCLC 56 placebo 56 #mg/day [002] 56 subtrochanteric 56 SVR# 56 Crohn Disease Activity 56 seroconversion 56 Index CDAI 56 renal carcinoma 56 secondary efficacy endpoint 56 posaconazole 56 invasive ductal 56 TACE 56 BRCA1 mutation carriers 56 metastatic HRPC 56 blastic phase 56 mL/min/#.# m2 56 Adverse events 56 LPV r 56 resectable 56 dose cytarabine 56 μg doses 56 splenectomized 56 5 Fluorouracil 56 plus prednisone prednisolone 56 asymptomatic carotid stenosis 56 REYATAZ r 55 copies ml 55 ABC/3TC 55 myeloablative 55 Adjuvant chemotherapy 55 adjuvant radiotherapy 55 genotypic resistance 55 mapatumumab 55 mCi 55 RRMS patients 55 EDSS scores 55 null responders 55 ischemic cardiomyopathy 55 CIMZIA TM certolizumab pegol 55 nadroparin 55 placebo p = 55 cytogenetic abnormalities 55 postop 55 KRAS mutations 55 epirubicin cyclophosphamide 55 ALT elevation 55 mIU ml 55 liver biopsies 55 dose regimens 55 medically inoperable 55 leukocyte count 55 CLARITY study 55 tPSA 55 DMARD therapy 55 goserelin 55 mg q8h 55 Follicular Lymphoma 55 Solid Tumors RECIST 55 thrombocytopenic 55 baseline neutrophil counts 55 subcutaneous enoxaparin 55 FOLPI 55 paclitaxel chemotherapy 55 QRS duration 55 HER2 positive tumors 55 castrate resistant 55 sorafenib Nexavar 55 interferon alfa 2b 55 debulking surgery 55 mg dL 55 severe hypoglycemic 55 HNSCC 55 deep venous thromboses 55 care regimens CCR 55 FROVA 55 sirolimus 55 alanine aminotransferase ALT 55 metastatic bladder 55 mg kg belimumab 55 idraparinux 55 peginterferon alfa 2b 55 trastuzumab Herceptin R 55 creatinine clearance 55 active comparator 55 TroVax ® 55 Ishak fibrosis score 55 metastatic malignant 55 severe renal impairment 55 mcg doses 55 experienced virologic failure 55 virological response 55 mcg BID 55 monotherapy 55 prostate cancer CRPC 55 fluoropyrimidine 55 prostate carcinoma 55 TEAEs 55 mg kg 55 eosinophilic asthma 55 glycated hemoglobin levels 55 complete remissions 55 -#.# log# copies mL 55 nadolol 55 HER2 positive cancers 55 MGd 55 seropositivity 55 mg kg Hematide 55 #Gy 55 hepatic metastases 55 reinfarction 55 relapsed refractory multiple myeloma 55 PREZISTA r arm 55 laboratory abnormalities 55 BRIM2 55 placebo p 55 mU L 55 lispro 55 target lesion revascularization 55 WBRT alone 55 acute STEMI 55 achieved mucosal healing 55 Pemetrexed 55 rimonabant #mg 55 T1c 55 grade gliomas 55 ARCOXIA 55 ara C 55 mutated KRAS 55 5FU 55 chronic GVHD 55 prostate cancer HRPC 55 diagnosed multiple myeloma 55 non squamous NSCLC 55 fluvastatin 55 ipsilateral breast 55 antiandrogen 55 colorectal carcinoma 55 cyclophosphamide methotrexate 55 relapsed CLL 55 melphalan prednisone 55 liver metastasis 55 taxane refractory 55 XIENCE V demonstrated 55 radioiodine therapy 55 ARB telmisartan 55 biliary tract cancer 55 galiximab 55 mg q#h 55 dexamethasone Decadron 55 fallopian tube carcinoma 55 BR.# 55 mEq L 55 recurrent myocardial infarction 55 ejection fractions 55 mIU L 55 microgram kg 55 DOXIL 55 Secondary endpoints 55 telaprevir dosing 55 IFN α 55 confidence interval #.#-#.# 55 GVAX 55 tumor resection 55 mg qd 55 mCi m 2 55 nicardipine 55 axitinib 55 undetectable PSA 55 disease progression TTP 55 adjuvant radiation 55 docetaxel Taxotere ® 55 HCV genotype 1 55 mg dose 55 troponin T 55 ≥ 55 breastfed exclusively 55 HER2 expression 55 TAXUS 55 seronegative 55 grade cervical intraepithelial 55 soft tissue sarcomas 55 -#.# log# 55 lymph node metastases 55 reach statistical significance 55 concurrent chemoradiation 55 chemotherapeutic regimens 55 ancrod 55 Pharmacokinetic parameters 55 Xelox 55 serum prostate 55 CHD CVD 55 p# biomarker 55 BENICAR HCT 55 irinotecan cisplatin 55 Hurthle cell 55 radical prostatectomy RP 55 hemoglobin A1c levels 55 urate lowering therapy 55 Renal Cell Carcinoma RCC 55 neoadjuvant radiation 55 hormone refractory prostate cancer 55 #mg dosing group 54 low dose dexamethasone 54 castrate resistant prostate cancer 54 recurrent GBM patients 54 BRIM3 54 Breslow thickness 54 nucleoside naive 54 treatment naïve genotype 54 ribavirin therapy 54 doxazosin 54 recurrent glioblastoma 54 APTIVUS r 54 TAXUS Liberte Long 54 cilengitide 54 morphometric vertebral fractures 54 contralateral breast 54 abdominal irradiation 54 resistant hormone refractory 54 refractory AML 54 IELT 54 chronic plaque psoriasis 54 DAS# scores 54 Expanded Disability Status 54 small lymphocytic lymphoma 54 events MACE 54 liposomal doxorubicin 54 postoperatively 54 placebo intravenously 54 epoetin alfa 54 patients undergoing CABG 54 refractory chronic lymphocytic 54 follicular lymphomas 54 lung metastasis 54 CYPHER R Sirolimus eluting 54 log# 54 Elitek 54 TTM = trailing 54 metastatic gastric 54 axillary lymph nodes 54 recurrent atrial fibrillation 54 null responder HCV 54 lamivudine 54 events AEs 54 liver transplant recipients 54 tumor regression 54 postoperative mortality 54 colorectal adenoma 54 #mg q8h 54 peginterferon alpha 2a 54 ± SD 54 T1a 54 HGPIN 54 rituximab refractory 54 cEVR 54 mitoxantrone chemotherapy 54 TMC# r 54 dose melphalan 54 urinary N telopeptide 54 dosing cohort 54 Hb A1C 54 forodesine 54 inhaled tobramycin 54 paricalcitol 54 hip BMD 54 #.#mg/dL 54 HBeAg 54 IIIa inhibitors 54 System IPSS 54 HER2 positive breast cancer 54 chronic myeloid 54 GSTP1 54 nonsquamous 54 lymphoma CTCL 54 RECIST 54 evaluating tivozanib 54 docetaxel Taxotere 54 BRCA2 mutation carriers 54 BRCA mutation carriers 54 radiotherapy RT 54 nab paclitaxel 54 pooled comparator 54 weekly intravenous infusions 54 n = 54 metastatic CRC 54 pemetrexed 54 stage IIIA 54 TAVR 54 advanced unresectable 54 hemodynamically significant 54 rFVIIa 54 myocardial infarction MI 54 histologic 54 leukopenia 54 serum IGF 54 intravesical therapy 54 daily subcutaneous injections 54 eribulin mesylate 54 anemia hemoglobin 54 virologic responses 54 dexamethasone 54 cytokine refractory 54 symptomatic BPH 54 serum urate 54 chronic HCV genotype 54 Halaven 54 VT VF 54 thromboembolic events 54 mU liter 54 ug dose 54 mcg kg REBETOL 54 β blockers 54 desvenlafaxine succinate 54 transaminase elevations 54 FDG PET scans 54 NSCLC 54 cART 54 undetectable hepatitis C 54 timepoint 54 cytologically confirmed 54 mcg mL 54 gp# vaccine 54 hepatocellular carcinomas 54 abiraterone acetate 54 IV malignant melanoma 54 relapsing multiple sclerosis 54 gout flares 54 NEVO ™ 54 cells uL 54 IV metastatic melanoma 54 allogeneic stem cell 54 #mg doses [002] 54 WBRT plus 54 imipenem 54 trabectedin 54 demonstrated antitumor activity 54 doripenem 54 lupus nephritis 54 perioperative complications 54 â ‰ ¥ 54 Glioblastoma Multiforme 54 vertebral fracture 54 carcinoid 54 q8h 54 non splenectomized 54 neutrophil counts 54 HIV uninfected 54 NLX P# 54 venous thromboembolism 54 capecitabine 54 lactate dehydrogenase LDH 54 postdose 54 aplastic anemia AA 54 relapsed ALL 54 retinal thickness 54 ug kg 54 prostate adenocarcinoma 54 adjuvant hormonal therapy 54 T2DM 54 recurrent malignant glioma 54 adenoma recurrence 54 sunitinib Sutent 54 Complication rates 54 % CI #.#-#.# [006] 54 hour bronchodilation 54 erlotinib 54 undergoing radical prostatectomy 54 zoledronic acid 54 cediranib 54 MVax R 54 DAS# remission 54 hypophosphatemia 54 malignant pleural mesothelioma 54 moderate renal impairment 54 Acute Myelogenous Leukemia AML 54 temozolomide 54 recurrent metastatic 54 tumor xenograft models 54 coronary revascularization 54 nodular partial response 54 Lauren Petitbois 54 NRTI sparing 54 mIU mL 54 treatment naive genotype 54 DMARD 54 taxane therapy 54 breast carcinoma 54 nonmetastatic prostate cancer 54 plus ribavirin 54 bevacizumab 54 endometrial thickness 54 pancreatic carcinoma 54 MYCN amplification 54 calcineurin inhibitor 54 smoldering myeloma 54 tocilizumab 54 mg p = 54 relapsing remitting MS RRMS 54 nmol L 54 nilotinib 54 receiving INTRON 54 cutaneous melanoma 54 Pegasys ® 54 oral deforolimus 54 Thal Dex 54 annualized relapse 54 tipranavir ritonavir 54 prior relapsers 54 intermittent dosing 54 cyclophosphamide doxorubicin vincristine 54 ductal breast cancer 54 radical cystectomy 54 EURIDIS 54 diameter stenosis 54 vincristine doxorubicin 54 hepatic resection 54 anastrozole 54 androgen suppression therapy 54 sorafenib tablets 54 binary restenosis rate 54 transplant ASCT 54 injected subcutaneously 54 tiotropium 54 neostigmine 54 pathologic fractures 54 HCV RNA 54 pheochromocytoma 54 mg kg cohorts 54 adjunctive ABILIFY 54 clinically meaningful improvement 54 reintervention 54 oral ridaforolimus 54 MMSE scores 54 briakinumab 53 Hepsera 53 gemcitabine cisplatin 53 untreated AML 53 degarelix 53 carcinoid tumors 53 MBq 53 refractory multiple myeloma 53 paclitaxel carboplatin 53 resected 53 anthracyclines taxanes 53 sorafenib 53 symptomatic intracerebral hemorrhage 53 tanned indoors 53 surgical debulking 53 prognostic variables 53 HIV seronegative